Gt biopharma to participate in the 3rd annual roth healthcare opportunities conference

San francisco, california, sept. 26, 2024 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager trike® platform, today announced that dr. jeffrey miller, md1, from the university of minnesota medical school2 and gt biopharma's consulting senior medical director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (aml) and myelodysplastic syndrome (mds) at the 3rd annual roth healthcare opportunities conference taking place october 9, 2024 in new york, ny. company management will also be participating in 1x1 meetings during the event.
GTBP Ratings Summary
GTBP Quant Ranking